Non-deletional Hemoglobin H disease occurs when a non-deletional α-globin gene mutation is present alongside the HbH genotype (--/αTα). This sub-type carries a distinct and often more challenging clinical profile compared with deletional forms, and requires a specifically tailored management approach.
Clinical phenotypes are diverse among patients with non-deletional HbH disease. The condition is generally associated with a more severe clinical course than deletional HbH disease, reflecting the nature of the underlying non-deletional α-globin mutation.
A key component of management involves folic acid supplementation to meet the demands of increased erythropoietic activity; the complete protocol — including full clinical guidance and contraindications — is available below.
Clinical phenotypes are diverse among affected individuals with non-deletional haemoglobin H (HbH) disease (--/αTα).
Clinical symptoms of non-deletional HbH are generally more severe than those of deletional forms.
Supplementation with folic acid ranging from 1 to 5 mg per day is generally recommended for all patients with non-deletional HbH disease, as it is required for increased erythropoietic activity.
Iron supplements should therefore be avoided.
View source ↗